Pdt Partners, LLC Enanta Pharmaceuticals Inc Transaction History

Pdt Partners, LLC

$1.01 Billion
Q1 2024

A detailed history of Pdt Partners, LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Pdt Partners, LLC holds 39,727 shares of ENTA stock, worth $515,259. This represents 0.07% of its overall portfolio holdings.

Number of Shares

39,727

Previous 63,225 37.17%

Holding current value

$515,259

Previous $594,000 16.67%

% of portfolio

0.07%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $236,859 - $410,275	-23,498 Reduced 37.17%	39,727 $693,000
Q4 2023 Feb 14, 2024	SELL	$8.18 - $10.78 $33,480 - $44,122	-4,093 Reduced 6.08%	63,225 $594,000
Q3 2023 Nov 14, 2023	BUY	$11.09 - $22.13 $440,261 - $878,538	39,699 Added 143.74%	67,318 $751,000
Q2 2023 Aug 14, 2023	BUY	$20.68 - $39.85 $571,160 - $1.1 Million	27,619 New	27,619 $591,000
Q2 2022 Aug 15, 2022	BUY	$38.13 - $76.93 $442,193 - $892,157	11,597 New	11,597 $548,000

Q4 2021 Feb 14, 2022	SELL	$60.19 - $97.37 $779,701 - $1.26 Million	-12,954 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $407,984 - $583,332	-9,946 Reduced 43.43%	12,954 $736,000
Q2 2021 Aug 16, 2021	BUY	$43.76 - $53.11 $137,275 - $166,606	3,137 Added 15.87%	22,900 $1.01 Million
Q1 2021 May 17, 2021	SELL	$41.69 - $54.95 $172,471 - $227,328	-4,137 Reduced 17.31%	19,763 $975,000
Q4 2020 Feb 16, 2021	BUY	$41.16 - $47.47 $185,219 - $213,615	4,500 Added 23.2%	23,900 $1.01 Million
Q3 2020 Nov 16, 2020	SELL	$43.36 - $53.53 $413,741 - $510,783	-9,542 Reduced 32.97%	19,400 $888,000
Q2 2020 Aug 14, 2020	BUY	$46.37 - $57.58 $1.34 Million - $1.67 Million	28,942 New	28,942 $1.45 Million

Others Institutions Holding ENTA

# of Institutions

108

Shares Held

21.7M

Call Options Held

9.4K

Put Options Held

3.3K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $269M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account